{"id":785913,"date":"2023-09-25T10:16:57","date_gmt":"2023-09-25T14:16:57","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/scilex-holding-company-announces-the-state-of-indiana-medicaid-will-add-elyxyb-as-a-preferred-agent-to-its-preferred-drug-list-pdl-effective-october-1-2023\/"},"modified":"2023-09-25T10:16:57","modified_gmt":"2023-09-25T14:16:57","slug":"scilex-holding-company-announces-the-state-of-indiana-medicaid-will-add-elyxyb-as-a-preferred-agent-to-its-preferred-drug-list-pdl-effective-october-1-2023","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/scilex-holding-company-announces-the-state-of-indiana-medicaid-will-add-elyxyb-as-a-preferred-agent-to-its-preferred-drug-list-pdl-effective-october-1-2023\/","title":{"rendered":"Scilex Holding Company announces the State of Indiana Medicaid will add Elyxyb as a preferred agent to its preferred drug list (PDL) effective October 1, 2023"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">PALO ALTO, Calif., Sept.  25, 2023  (GLOBE NEWSWIRE) &#8212; Scilex Holding Company (Nasdaq: SCLX, \u201cScilex\u201d or \u201cCompany\u201d), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, announced the State of Indiana Medicaid will add Elyxyb as a preferred agent to its Preferred Drug List (\u201cPDL\u201d) effective October 1, 2023.<\/p>\n<p>As Indiana is a Single PDL State, where the five Indiana Managed Medicaid plans (Anthem, CareSource, MDwise, Managed Health Services (MHS), and UnitedHealthcare) must follow the State PDL, this change improves access to Elyxyb for all eligible patients under the Indiana Medicaid umbrella, the combined traditional Medicaid and Managed Medicaid populations, totaling approximately 1.2M lives, between the ages of 18-64.<\/p>\n<p>Under the new terms, Elyxyb will be Preferred with the following prior authorization (PA) criteria:<\/p>\n<ul>\n<li>Migraine Dx, 18 &amp; Older<\/li>\n<li>Trial and failure of 1 preferred triptan or contraindication to triptans<\/li>\n<li>Elyxyb will have a QL of 6 bottles.<\/li>\n<\/ul>\n<p>\u201cWe are pleased to announce our first Elyxyb managed health care win with the Medicaid plan in Indiana, which we believe is an important step to expand utilization of Elyxyb throughout the U.S. Importantly, our diversified portfolio of unique, leading programs will increasingly allow us to offer patients complementary and standalone opioid-sparing outpatient pain management solutions,\u201d said Jaisim Shah, Chief Executive Officer of Scilex Holding Company.<\/p>\n<p>\n        <strong>About Scilex Holding Company <\/strong>\n      <\/p>\n<p>Scilex Holding Company is an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Scilex is uncompromising in its focus to become the global pain management leader committed to social, environmental, economic, and ethical principles to responsibly develop pharmaceutical products to maximize quality of life. Results from the Phase III Pivotal Trial C.L.E.A.R. Program for SEMDEXA<sup>TM<\/sup>, its novel, non-opioid product for the treatment of lumbosacral radicular pain (sciatica), were announced in March 2022. Scilex participated in the type C meeting for purposes of pre-NDA discussion with the FDA and is pending official minutes in writing from the FDA. Scilex targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with moderate to severe pain.\u00a0 Scilex launched its first commercial product ZTlido\u00ae in October 2018, in-licensed a commercial product Gloperba\u00ae in June 2022, and launched its third FDA-approved product Elyxyb<sup>TM<\/sup> in April 2023. It is also developing its late-stage pipeline, which includes a pivotal Phase 3 candidate, and one Phase 2 and one Phase 1 candidate.\u00a0 Its commercial product, ZTlido\u00ae (lidocaine topical system) 1.8%, or ZTlido\u00ae, is a prescription lidocaine topical product approved by the U.S. Food and Drug Administration for the relief of pain associated with post-herpetic neuralgia, which is a form of post-shingles nerve pain.\u00a0 Scilex in-licensed the exclusive right to commercialize Gloperba\u00ae (colchicine USP) oral solution, an FDA-approved prophylactic treatment for painful gout flares in adults, in the U.S. Scilex in-licensed the exclusive rights to commercialize Elyxyb<sup>TM<\/sup> (celecoxib oral solution) in the U.S. and Canada, the only FDA-approved ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults. Scilex launched Elyxyb<sup>TM<\/sup> in April 2023, and is planning to commercialize Gloperba\u00ae by 2024, and is well-positioned to market and distribute those products.\u00a0\u00a0 Scilex\u2019s three product candidates are SP-102 (injectable dexamethasone sodium phosphate viscous gel product containing 10 mg dexamethasone), or SEMDEXA\u2122, a Phase 3, novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica, with FDA Fast Track status; SP-103 (lidocaine topical system) 5.4%, a Phase 2 study, triple-strength formulation of ZTlido\u00ae, for the treatment of acute low back pain, with FDA Fast Track status; and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule, for the treatment of chronic pain, fibromyalgia that has completed multiple Phase 1 trial programs and is expected to initiate Phase 2 trials in 2024.<\/p>\n<p>Scilex Holding Company is headquartered in Palo Alto, California.<\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p>This press release and any statements made for and during any presentation or meeting concerning the matters discussed in this press release contain forward-looking statements related to Scilex and its subsidiaries under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements regarding the potential growth of Elyxyb in managed care plans, the potential benefits related to the addition of Elyxyb to the State of Indiana Medicaid PDL, Scilex\u2019s belief that it is well positioned to continue its growth over the next several years, Scilex\u2019s long-term objectives and commercialization plans, Scilex\u2019s potential to attract new capital, future opportunities for Scilex, Scilex\u2019s future business strategies, the expected cash resources of Scilex and the expected uses thereof; Scilex\u2019s current and prospective product candidates, planned clinical trials and preclinical activities and potential product approvals, as well as the potential for market acceptance of any approved products and the related market opportunity; statements regarding ZTlido\u00ae, Gloperba\u00ae, ELYXYB\u00ae<strong>,<\/strong> SP-102 (SEMDEXA\u2122), SP-103 or SP-104, if approved by the FDA; Scilex\u2019s development and commercialization plans; and Scilex\u2019s products, technologies and prospects. \u00a0<\/p>\n<p>Risks and uncertainties that could cause Scilex\u2019s actual results to differ materially and adversely from those expressed in our forward-looking statements, include, but are not limited to: risks associated with the unpredictability of trading markets and whether a market will be established for Scilex\u2019s common stock; general economic, political and business conditions; risks related to the ongoing COVID-19 pandemic; the risk that the potential product candidates that Scilex develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all; risks relating to uncertainty regarding the regulatory pathway for Scilex\u2019s product candidates; the risk that Scilex will be unable to successfully market or gain market acceptance of its product candidates; the risk that Scilex\u2019s product candidates may not be beneficial to patients or successfully commercialized; the risk that Scilex has overestimated the size of the target patient population, their willingness to try new therapies and the willingness of physicians to prescribe these therapies; risks that the outcome of the trials for SP-103 or SP-104 may not be successful; risks that the prior results of the clinical trials of SP-102 (SEMDEXA\u2122), SP-103 or SP-104 may not be replicated; regulatory and intellectual property risks; and other risks and uncertainties indicated from time to time and other risks set forth in Scilex\u2019s filings with the Securities and Exchange Commission. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and Scilex undertakes no obligation to update any forward-looking statement in this press release except as may be required by law.<\/p>\n<p align=\"justify\">\n        <strong>Contacts:<\/strong>\n      <\/p>\n<p>Investors and Media<br \/>Scilex Holding Company <br \/>960 San Antonio Road<br \/>Palo Alto, CA 94303<br \/>Office: (650) 516-4310<\/p>\n<p>Email: investorrelations@scilexholding.com<\/p>\n<p>Website: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Y--lSBulvhDyd6kFRWrP3NC7POEuZN0-6cHhGrA-5CPkgyZUCsiggFRQADCy0Gr3y9LKmp2YBnpp1n0Vz4Ngsvffj6RKSFQv3zGyPp7PGTY=\" rel=\"nofollow noopener\" target=\"_blank\">www.scilexholding.com<\/a><\/p>\n<p>\n        \n      <\/p>\n<p align=\"justify\">SEMDEXA\u2122 (SP-102) is a trademark owned by Semnur Pharmaceuticals, Inc., a wholly-owned subsidiary of Scilex Holding Company. A proprietary name review by the FDA is planned.<\/p>\n<p align=\"justify\">ZTlido\u00ae is a registered trademark owned by Scilex Pharmaceuticals Inc., a wholly-owned subsidiary of Scilex Holding Company.<\/p>\n<p align=\"justify\">Gloperba\u00ae is the subject of an exclusive, transferable license to use the registered trademark by Scilex Holding Company.<\/p>\n<p align=\"justify\">ELYXYB\u00ae is the subject of an exclusive, transferable license to use the trademark by Scilex Holding Company.<\/p>\n<p align=\"justify\">All other trademarks are the property of their respective owners.<\/p>\n<p align=\"justify\">\u00a9 2023 Scilex Holding Company All Rights Reserved.<\/p>\n<p \/>\n      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkyNzQ2OSM1ODI5NjEyIzIyNTQ3Mjc=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/NWM1NTNiNDUtNTRkNy00OGY4LThlNGMtMjM5OGQxODcyNWUyLTEyNjYyNzY=\/tiny\/Scilex-Holding-Company.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>PALO ALTO, Calif., Sept. 25, 2023 (GLOBE NEWSWIRE) &#8212; Scilex Holding Company (Nasdaq: SCLX, \u201cScilex\u201d or \u201cCompany\u201d), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, announced the State of Indiana Medicaid will add Elyxyb as a preferred agent to its Preferred Drug List (\u201cPDL\u201d) effective October 1, 2023. As Indiana is a Single PDL State, where the five Indiana Managed Medicaid plans (Anthem, CareSource, MDwise, Managed Health Services (MHS), and UnitedHealthcare) must follow the State PDL, this change improves access to Elyxyb for all eligible patients under the Indiana Medicaid umbrella, the combined traditional Medicaid and Managed Medicaid populations, totaling approximately 1.2M lives, between the ages &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/scilex-holding-company-announces-the-state-of-indiana-medicaid-will-add-elyxyb-as-a-preferred-agent-to-its-preferred-drug-list-pdl-effective-october-1-2023\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Scilex Holding Company announces the State of Indiana Medicaid will add Elyxyb as a preferred agent to its preferred drug list (PDL) effective October 1, 2023&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-785913","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.1 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Scilex Holding Company announces the State of Indiana Medicaid will add Elyxyb as a preferred agent to its preferred drug list (PDL) effective October 1, 2023 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/scilex-holding-company-announces-the-state-of-indiana-medicaid-will-add-elyxyb-as-a-preferred-agent-to-its-preferred-drug-list-pdl-effective-october-1-2023\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Scilex Holding Company announces the State of Indiana Medicaid will add Elyxyb as a preferred agent to its preferred drug list (PDL) effective October 1, 2023 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PALO ALTO, Calif., Sept. 25, 2023 (GLOBE NEWSWIRE) &#8212; Scilex Holding Company (Nasdaq: SCLX, \u201cScilex\u201d or \u201cCompany\u201d), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, announced the State of Indiana Medicaid will add Elyxyb as a preferred agent to its Preferred Drug List (\u201cPDL\u201d) effective October 1, 2023. As Indiana is a Single PDL State, where the five Indiana Managed Medicaid plans (Anthem, CareSource, MDwise, Managed Health Services (MHS), and UnitedHealthcare) must follow the State PDL, this change improves access to Elyxyb for all eligible patients under the Indiana Medicaid umbrella, the combined traditional Medicaid and Managed Medicaid populations, totaling approximately 1.2M lives, between the ages &hellip; Continue reading &quot;Scilex Holding Company announces the State of Indiana Medicaid will add Elyxyb as a preferred agent to its preferred drug list (PDL) effective October 1, 2023&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/scilex-holding-company-announces-the-state-of-indiana-medicaid-will-add-elyxyb-as-a-preferred-agent-to-its-preferred-drug-list-pdl-effective-october-1-2023\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-09-25T14:16:57+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkyNzQ2OSM1ODI5NjEyIzIyNTQ3Mjc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/scilex-holding-company-announces-the-state-of-indiana-medicaid-will-add-elyxyb-as-a-preferred-agent-to-its-preferred-drug-list-pdl-effective-october-1-2023\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/scilex-holding-company-announces-the-state-of-indiana-medicaid-will-add-elyxyb-as-a-preferred-agent-to-its-preferred-drug-list-pdl-effective-october-1-2023\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Scilex Holding Company announces the State of Indiana Medicaid will add Elyxyb as a preferred agent to its preferred drug list (PDL) effective October 1, 2023\",\"datePublished\":\"2023-09-25T14:16:57+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/scilex-holding-company-announces-the-state-of-indiana-medicaid-will-add-elyxyb-as-a-preferred-agent-to-its-preferred-drug-list-pdl-effective-october-1-2023\\\/\"},\"wordCount\":1261,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/scilex-holding-company-announces-the-state-of-indiana-medicaid-will-add-elyxyb-as-a-preferred-agent-to-its-preferred-drug-list-pdl-effective-october-1-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkyNzQ2OSM1ODI5NjEyIzIyNTQ3Mjc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/scilex-holding-company-announces-the-state-of-indiana-medicaid-will-add-elyxyb-as-a-preferred-agent-to-its-preferred-drug-list-pdl-effective-october-1-2023\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/scilex-holding-company-announces-the-state-of-indiana-medicaid-will-add-elyxyb-as-a-preferred-agent-to-its-preferred-drug-list-pdl-effective-october-1-2023\\\/\",\"name\":\"Scilex Holding Company announces the State of Indiana Medicaid will add Elyxyb as a preferred agent to its preferred drug list (PDL) effective October 1, 2023 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/scilex-holding-company-announces-the-state-of-indiana-medicaid-will-add-elyxyb-as-a-preferred-agent-to-its-preferred-drug-list-pdl-effective-october-1-2023\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/scilex-holding-company-announces-the-state-of-indiana-medicaid-will-add-elyxyb-as-a-preferred-agent-to-its-preferred-drug-list-pdl-effective-october-1-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkyNzQ2OSM1ODI5NjEyIzIyNTQ3Mjc=\",\"datePublished\":\"2023-09-25T14:16:57+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/scilex-holding-company-announces-the-state-of-indiana-medicaid-will-add-elyxyb-as-a-preferred-agent-to-its-preferred-drug-list-pdl-effective-october-1-2023\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/scilex-holding-company-announces-the-state-of-indiana-medicaid-will-add-elyxyb-as-a-preferred-agent-to-its-preferred-drug-list-pdl-effective-october-1-2023\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/scilex-holding-company-announces-the-state-of-indiana-medicaid-will-add-elyxyb-as-a-preferred-agent-to-its-preferred-drug-list-pdl-effective-october-1-2023\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkyNzQ2OSM1ODI5NjEyIzIyNTQ3Mjc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkyNzQ2OSM1ODI5NjEyIzIyNTQ3Mjc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/scilex-holding-company-announces-the-state-of-indiana-medicaid-will-add-elyxyb-as-a-preferred-agent-to-its-preferred-drug-list-pdl-effective-october-1-2023\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Scilex Holding Company announces the State of Indiana Medicaid will add Elyxyb as a preferred agent to its preferred drug list (PDL) effective October 1, 2023\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Scilex Holding Company announces the State of Indiana Medicaid will add Elyxyb as a preferred agent to its preferred drug list (PDL) effective October 1, 2023 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/scilex-holding-company-announces-the-state-of-indiana-medicaid-will-add-elyxyb-as-a-preferred-agent-to-its-preferred-drug-list-pdl-effective-october-1-2023\/","og_locale":"en_US","og_type":"article","og_title":"Scilex Holding Company announces the State of Indiana Medicaid will add Elyxyb as a preferred agent to its preferred drug list (PDL) effective October 1, 2023 - Market Newsdesk","og_description":"PALO ALTO, Calif., Sept. 25, 2023 (GLOBE NEWSWIRE) &#8212; Scilex Holding Company (Nasdaq: SCLX, \u201cScilex\u201d or \u201cCompany\u201d), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, announced the State of Indiana Medicaid will add Elyxyb as a preferred agent to its Preferred Drug List (\u201cPDL\u201d) effective October 1, 2023. As Indiana is a Single PDL State, where the five Indiana Managed Medicaid plans (Anthem, CareSource, MDwise, Managed Health Services (MHS), and UnitedHealthcare) must follow the State PDL, this change improves access to Elyxyb for all eligible patients under the Indiana Medicaid umbrella, the combined traditional Medicaid and Managed Medicaid populations, totaling approximately 1.2M lives, between the ages &hellip; Continue reading \"Scilex Holding Company announces the State of Indiana Medicaid will add Elyxyb as a preferred agent to its preferred drug list (PDL) effective October 1, 2023\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/scilex-holding-company-announces-the-state-of-indiana-medicaid-will-add-elyxyb-as-a-preferred-agent-to-its-preferred-drug-list-pdl-effective-october-1-2023\/","og_site_name":"Market Newsdesk","article_published_time":"2023-09-25T14:16:57+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkyNzQ2OSM1ODI5NjEyIzIyNTQ3Mjc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/scilex-holding-company-announces-the-state-of-indiana-medicaid-will-add-elyxyb-as-a-preferred-agent-to-its-preferred-drug-list-pdl-effective-october-1-2023\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/scilex-holding-company-announces-the-state-of-indiana-medicaid-will-add-elyxyb-as-a-preferred-agent-to-its-preferred-drug-list-pdl-effective-october-1-2023\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Scilex Holding Company announces the State of Indiana Medicaid will add Elyxyb as a preferred agent to its preferred drug list (PDL) effective October 1, 2023","datePublished":"2023-09-25T14:16:57+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/scilex-holding-company-announces-the-state-of-indiana-medicaid-will-add-elyxyb-as-a-preferred-agent-to-its-preferred-drug-list-pdl-effective-october-1-2023\/"},"wordCount":1261,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/scilex-holding-company-announces-the-state-of-indiana-medicaid-will-add-elyxyb-as-a-preferred-agent-to-its-preferred-drug-list-pdl-effective-october-1-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkyNzQ2OSM1ODI5NjEyIzIyNTQ3Mjc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/scilex-holding-company-announces-the-state-of-indiana-medicaid-will-add-elyxyb-as-a-preferred-agent-to-its-preferred-drug-list-pdl-effective-october-1-2023\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/scilex-holding-company-announces-the-state-of-indiana-medicaid-will-add-elyxyb-as-a-preferred-agent-to-its-preferred-drug-list-pdl-effective-october-1-2023\/","name":"Scilex Holding Company announces the State of Indiana Medicaid will add Elyxyb as a preferred agent to its preferred drug list (PDL) effective October 1, 2023 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/scilex-holding-company-announces-the-state-of-indiana-medicaid-will-add-elyxyb-as-a-preferred-agent-to-its-preferred-drug-list-pdl-effective-october-1-2023\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/scilex-holding-company-announces-the-state-of-indiana-medicaid-will-add-elyxyb-as-a-preferred-agent-to-its-preferred-drug-list-pdl-effective-october-1-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkyNzQ2OSM1ODI5NjEyIzIyNTQ3Mjc=","datePublished":"2023-09-25T14:16:57+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/scilex-holding-company-announces-the-state-of-indiana-medicaid-will-add-elyxyb-as-a-preferred-agent-to-its-preferred-drug-list-pdl-effective-october-1-2023\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/scilex-holding-company-announces-the-state-of-indiana-medicaid-will-add-elyxyb-as-a-preferred-agent-to-its-preferred-drug-list-pdl-effective-october-1-2023\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/scilex-holding-company-announces-the-state-of-indiana-medicaid-will-add-elyxyb-as-a-preferred-agent-to-its-preferred-drug-list-pdl-effective-october-1-2023\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkyNzQ2OSM1ODI5NjEyIzIyNTQ3Mjc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkyNzQ2OSM1ODI5NjEyIzIyNTQ3Mjc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/scilex-holding-company-announces-the-state-of-indiana-medicaid-will-add-elyxyb-as-a-preferred-agent-to-its-preferred-drug-list-pdl-effective-october-1-2023\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Scilex Holding Company announces the State of Indiana Medicaid will add Elyxyb as a preferred agent to its preferred drug list (PDL) effective October 1, 2023"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/785913","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=785913"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/785913\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=785913"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=785913"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=785913"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}